Translational Development Acquisition Corp

Translational Development Acquisition Corp(TDAC)の財務

$10.910

+0.050 (+0.46%)終値時点

TDAC の収益性とマージン

Evaluating the bottom line, Translational Development Acquisition Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 3.44%, provide a clear picture of how effectively TDAC converts its operational activities into shareholder value.

TDAC の同業比較

In the context of the broader market, TDAC competes directly with industry leaders such as LIEN and THEO. With a market capitalization of $209.71M, it holds a leading position in the sector. When comparing efficiency, TDAC's gross margin of N/A stands against LIEN's 84.49% and THEO's N/A. Such benchmarking helps identify whether Translational Development Acquisition Corp is trading at a premium or discount relative to its financial performance.

Translational Development Acquisition Corp の財務パフォーマンス

TDAC's recent financial performance shows a net income of $1,662,122 for Q3 2025, demonstrating profitability, although it faced a significant loss in Q4 2025 with a net income of -$553,290. The forward P/E ratio is currently 0, reflecting uncertainty in future earnings.

Financials

FY2026Q2
YoY:
-100.00%
0.00
Total Revenue
FY2026Q2
YoY:
+198.95%
-661.05K
Operating Profit
FY2026Q2
YoY:
-41.66%
946.98K
Net Income after Tax
FY2026Q2
YoY:
-42.86%
0.04
EPS - Diluted
FY2026Q2
YoY:
+97.70%
-338.75K
Free Cash Flow
FY2024Q1
YoY:
+223.40%
-427.83
Gross Profit Margin - %
FY2024Q1
-33.48
FCF Margin - %
FY2024Q1
YoY:
+328.19%
-2.22K
Net Margin - %

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める